Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Sigma-Aldrich, Agilent Technologies

Premium

PerkinElmer announced this week the launch of a new chromatography software called version 6.3 TotalChrom Chromatography Data System. New features of the software include a fully CFR Part 11 compliant architecture, automated processing and a modern, intuitive interface. In addition, the software has “review and approve” features to quickly and easily examine numerous chromatograms and reports, and to electronically sign off and route approved data.


Sigma-Aldrich announced last week the introduction of its Panorama Ab Microarray Cell Signalling Kit, the first in a line of antibody-based microarrays.

Each Panorama Kit consists of 224 immobilized antibodies chosen from Sigma-Aldrich’s range of over 3,000. The kit uses a specialized format that maintains antibody activity and specificity within a three-dimensional structure of nitrocellulose layer. It has a high protein-binding capacity, dynamic range and reproducibility, the company said.


Agilent Technologies has introduced its pulsed dynamic focusing source for MALDI-MS. The source incorporates highly efficient, ion-focusing technology, a larger, more rugged source body, and upgraded imaging optics for easier target-spot selection.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.